Connect with us


GSK Drives Advances in AI and Emerging Technologies to Improve Healthcare

Emerging technologies are pivotal in healthcare. GSK’s María Cardenal-Iradier, Jorge Pou, and Sergio Ostalé presented to the IDIS Foundation’s Innovation Committee their proposals using AI to enhance R&D and patient care. Technologies like digital twins, 5G, synthetic data, and AI offer new capabilities but also pose regulatory and cybersecurity challenges. GSK’s initiatives aim to improve therapeutic innovation, clinical trials, and patient outcomes.




Currently, emerging technologies play a crucial role in the health sector. Thus, a few representatives from GSK, including María Cardenal-Iradier, Director of Market Access and Regulatory, and Sergio Ostalé, director of the Oncohematology area, presented to the Innovation Committee of the IDIS Foundation, the company’s innovation and AI proposals to improve R&D and the experience of patients in prevention and management of pathologies.

GSK: Healthcare faces challenges of continuous innovation

There are a large number of useful technologies in the healthcare sector, such as digital twins, which allow the behavior of complex systems to be simulated and predicted; 5G connectivity, which improves communication and access to data in real time; synthetic data, which facilitate the generation of virtual patients with statistical patterns similar to real ones without compromising the privacy of the latter; and artificial intelligence (AI) and generative artificial intelligence (Gen AI), which offer new analytical and predictive capabilities.

However, healthcare faces challenges of continuous and accelerated innovation, advances in healthcare technology, regulatory aspects and cybersecurity risks that must be resolved.

GSK presented the company’s innovation and AI proposals to improve R&D and the experience of patients in prevention and management of pathologies. Source

During the GSK meeting, it was explained that the technology allows shortening the development times of therapeutic innovations through the simulation of molecules

GSK representatives said hatt AI also helps with therapeutic targets, generation of synthetic data and improving adherence to trials. In addition, it is being used for the identification of eligible studies, the processing, analysis and classification of clinical trials and the extraction of data to assess the effectiveness and efficiency of the results.

Ángel de Benito: “IDIS Foundation is faithfully committed to digital innovation and focuses on sustainability and professional training”

At the same time, GSK’s role in promoting AI to stay ahead of the disease was also highlighted with projects such as OncoGYN, aimed at health professionals who treat gynecological cancer, such as ovarian or endometrial cancer.

Finally, the importance of introducing technology into healthcare circuits was mentioned by GSK representatives to help improve the processes of healthcare professionals and, therefore, the quality of life of patients.

Ángel de Benito, general secretary of the IDIS Foundation, stated that “the development of new technologies that improve the processes of professionals is, without a doubt, a measure to improve efficiency in medical care, which has a direct impact on quality. of patients’ lives, and therefore, an essential aspect for the IDIS Foundation, which is faithfully committed to digital innovation and focuses on sustainability and professional training.”


(Featured image by Ani Kolleshi via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.